Skip to main content

Table 2 Procedural characteristics: access site, antithrombotic therapy, and arterial flow status

From: Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

  N = 417
Femoral access   217 (52)
Radial access   200 (48)
Antithrombotic therapy
 No additional treatment   93 (22.3)
 UFH   153 (36.6)
  UFH 70 U/kg 115  
  UFH 100 U/kg 38  
 Enoxaparin   18 (4.3)
  Enoxaparin 0.35 mg/kg 3  
  Enoxaparin 0.5 mg/kg 15  
 Bivalirudin   24 (5.7)
  Bivalirudin in cath lab 10  
  Bivalirudin in cath lab +4 h 14  
 Abciximab   65 (15.5)
  Abciximab bolus 12  
  Abciximab bolus plus infusion 53  
 Abciximab plus UFH   44 (10.5)
  Abciximab bolus 18  
  Abciximab bolus plus infusion 26  
 Other regimens   20 (4.7)
Baseline flow
 TIMI 0   196 (47)
 TIMI 1   44 (10.5)
 TIMI 2   66 (15.8)
 TIMI 3   111 (26.6)
Final flow
 TIMI 0   13 (3.1)
 TIMI 1   9 (2.2)
 TIMI 2   22 (5.3)
 TIMI 3   373 (89.4)
  1. UFH unfractionated heparin